

1 **Type III interferons disrupt the lung epithelial barrier upon viral recognition.**

2  
3 Achille Broggi<sup>1,\*</sup>, Sreya Ghosh<sup>1,\*</sup>, Benedetta Sposito<sup>1,2,\*</sup>, Roberto Spreafico<sup>3</sup>, Fabio Balzarini<sup>1,2</sup>,  
4 Antonino Lo Cascio<sup>1,2</sup>, Nicola Clementi<sup>4</sup>, Maria De Santis<sup>5</sup>, Nicasio Mancini<sup>4,6</sup>, Francesca  
5 Granucci<sup>2,7</sup>, Ivan Zanoni<sup>1,2,8,#</sup>.

6  
7  
8 <sup>1</sup> Harvard Medical School, Boston Children's Hospital, Division of Immunology, Boston, United  
9 States.

10 <sup>2</sup> Department of Biotechnology and Biosciences, University of Milano - Bicocca, Milan, Italy.

11 <sup>3</sup> Institute for Quantitative and Computational Biosciences, University of California, Los Angeles,  
12 United States.

13 <sup>4</sup> Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan,  
14 Italy.

15 <sup>5</sup> Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center - IRCCS,  
16 Rozzano, Italy.

17 <sup>6</sup> IRCCS San Raffaele Hospital, Milan, Italy.

18 <sup>7</sup> INGM-National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" Milan, Italy.

19 <sup>8</sup> Harvard Medical School, Boston Children's Hospital, Division of Gastroenterology, Boston,  
20 United States.

21 \* Equal contribution

22 # Corresponding author: [ivan.zanoni@childrens.harvard.edu](mailto:ivan.zanoni@childrens.harvard.edu)

23

24

25

26

27 **Abstract.**

28 Lower respiratory tract infections are a leading cause of mortality driven by infectious  
29 agents. RNA viruses such as influenza virus, respiratory syncytial virus and the new pandemic  
30 coronavirus SARS-CoV-2 can be highly pathogenic. Clinical and experimental evidence indicate  
31 that most severe and lethal cases do not depend on the viral burden and are, instead,  
32 characterized by an aberrant immune response. In this work we assessed how the innate immune  
33 response contributes to the pathogenesis of RNA virus infections. We demonstrate that type III  
34 interferons produced by dendritic cells in the lung in response to viral recognition cause barrier  
35 damage and compromise the host tissue tolerance. In particular, type III interferons inhibit tissue  
36 repair and lung epithelial cell proliferation, causing susceptibility to lethal bacterial superinfections.  
37 Overall, our data give a strong mandate to rethink the pathophysiological roles of this group of  
38 interferons and their possible use in the clinical practice against endemic as well as emerging  
39 viral infections.

40

41

42 **Main text.**

43 The ability to resolve viral infections of the lung is dependent on the actions of interferons (IFNs)  
44 and inflammatory cytokines. These molecules are induced during viral infections, yet the relative  
45 contributions of each interferon or cytokine to host defense and a return to homeostasis remains  
46 undefined. In particular the actions of type III IFNs (IFN- $\lambda$ ) have attracted much attention, as  
47 these cytokines operate primarily at mucosal surfaces, in part due to the selective expression of  
48 the type III IFN receptor in epithelia and neutrophils (1–3). Recent work established that unlike  
49 their type I or II counterparts, type III IFN signaling induces antiviral activities while simultaneously  
50 minimizing the tissue destructive activity of neutrophils (4–6). When considered in the context of  
51 an increasing number of viral infections, including the recently emerged severe acute respiratory  
52 syndrome (SARS)-coronavirus (CoV)-2, where inflammation appears to be the primary driver of  
53 life threatening symptoms (7–12), the ability of type III IFNs to limit immunopathology but maintain  
54 antiviral activity is significant. Indeed, discussions on the possible use of IFN- $\lambda$  against SARS-  
55 COV-2 have begun (13) and a clinical trial (14) has been initiated with the human pegylated-IFN-  
56  $\lambda$ 1a. Despite this interest of the use of type III IFNs to treat viral infections, we know very little  
57 about the short- and long-term actions of this family of secreted factors.

58 During viral infections of the lung, immunopathology may predispose the host to opportunistic  
59 bacterial infections, referred to as superinfections, which take advantage of this unbalanced status  
60 and often lead to lethal consequences (15–17). In contrast to its protective effect against acute  
61 viral infections, IFN- $\lambda$  was found to decrease bacterial control in virus-bacteria superinfection  
62 models(18–20) . Whether this is due to the anti-inflammatory activity of IFN- $\lambda$  that results in a  
63 reduced resistance of the host to a subsequent bacterial infection or to the capacity of this group  
64 of interferons to alter the physiology of the lung upon a viral encounter remains unresolved. As  
65 of present the contribution of type III IFN to the human pathology of severe viral infections and  
66 bacterial superinfections is unknown. Superinfections represent the first cause of lethality upon  
67 influenza virus infection (21) and correlate with severity in coronavirus disease (COVID)-19

68 patients (11, 22–24). Mouse models of SARS, middle east respiratory syndrome (MERS) (25, 26)  
69 and influenza (5, 27–29) are characterized by a robust induction of IFN-λ, however, the  
70 involvement of this group of interferons in COVID-19 is more controversial. Although *in vitro*  
71 studies on nasal and bronchial primary epithelial cells demonstrate IFN-λ induction by SARS-  
72 CoV-2 (30), another study found a reduced production of both type I and type III IFNs *in vitro* and  
73 *ex vivo* (31).

74 To directly evaluate the capacity of SARS-CoV-2 to induce interferons in the upper or  
75 lower airways, we tested the presence of IFNs, and other inflammatory cytokines, in the swabs  
76 of COVID-19 patients and healthy controls, as well as the bronchoalveolar (BAL) fluid of severe  
77 SARS-CoV-2-positive patients. Although we confirmed that COVID-19 patients present a scarce  
78 production of inflammatory mediators in the upper airways, the BAL fluid of patients with severe  
79 disease presented elevated levels not only of inflammatory cytokines, but also of specific  
80 members of the type III IFN family (Fig. 1A-E). Thus, IFN-λ production is associated with the most  
81 pathogenic endemic as well as emerging RNA viral infections.

82 In order to directly evaluate the contribution of IFN-λ to the immune pathology driven by  
83 RNA respiratory viruses uncoupled from its effect on viral replication, we devised an experimental  
84 system in which pattern recognition receptors (PRR) involved in viral sensing were stimulated  
85 with their cognate ligands in mice that can, or cannot, respond to IFN-λ. RNA viruses are directly  
86 sensed by two major classes of PRR (32, 33) . Toll-like receptors (TLR) recognize viral nucleic  
87 acids in the endosomal compartment with TLR7 recognizing single-stranded RNA directly from  
88 virions in the endosomes (34) and TLR3 recognizing double-stranded RNA intermediate derived  
89 from dying infected cells (35). The cytosolic sensors retinoic acid-inducible gene I (RIG-I) and  
90 melanoma differentiation-associated protein 5 (MDA5) instead, recognize double strand and  
91 hairpin RNA from replicating viruses (32, 33) in association with the common adaptor  
92 mitochondrial antiviral signaling protein (MAVS). We thus intra-tracheally instilled the TLR7 ligand  
93 R848 and the synthetic analog of double-stranded RNA, polyinosine-polycytidylic acid (poly (I:C))

94 that stimulates both TLR3 and the RIG-I/MDA5-MAVS pathway *in vivo* (36, 37). Viral-sensing  
95 PPRs were stimulated over the course of six days to simulate prolonged innate immune activation  
96 in the lung. Only poly (I:C) treatment induced morbidity as measured by body weight and  
97 temperature drop (Fig. 1F and Fig. S1A), and only poly (I:C) treatment compromised barrier  
98 function as measured by the level of total protein and lactate dehydrogenase (LDH) in the  
99 bronchoalveolar lavage (BAL) (Fig. 1G and Fig. S1B). Increase in morbidity and decrease in  
100 barrier function correlated with the levels of IFN-I and IFN-λ, whose mRNAs are strongly  
101 upregulated in the lung of mice treated with poly (I:C) but not in mice treated with R848 (Fig. 1H,  
102 I). In contrast R848 treatment induced upregulation of pro inflammatory cytokines (i.e. IL-1β) but  
103 had no correlation with barrier function or temperature decrease (Fig. 1F-J).

104 Alterations in the epithelial barrier are known to predispose to lethal bacterial  
105 superinfections (38–40), we therefore infected mice treated with either R848 or poly (I:C) with  
106 *Staphylococcus aureus* (*S. aureus*). Only poly (I:C) treatment was sufficient to induce lethality  
107 upon *S. aureus* infection (Fig. 1K). Moreover poly (I:C) treated mice displayed a higher bacterial  
108 burden (Fig. 1L), a stronger hypothermia upon *S. aureus* infection, and higher barrier damage  
109 (Fig. S2A, B). *S. aureus* infection did not alter the pattern of IFN production as only poly (I:C)  
110 induces upregulation of interferons' mRNAs (Fig. S2C-E). While both IFN-I and IFN-λ transcripts  
111 are upregulated over time upon poly (I:C) treatment (Fig. S3A, B), IFN-I protein levels measured  
112 in whole lung lysates are low and plateau after 1d of treatment while IFN-λ protein levels increase  
113 over time (Fig. S3C, D) and their increase correlates with *S. aureus* bacterial burden (Fig. S3E).  
114 Moreover, transcript levels of CXCL10, which is induced by IFN-I and not by IFN-λ (5, 41) peak  
115 at day 1 and reach a plateau over the following days (Fig. S3F), consistent with IFN-I protein  
116 expression kinetics. Conversely, the expression of the interferon-stimulated gene (ISG) *Rsd2*,  
117 which is induced similarly by both IFN classes, increases over time and, thus, correlates with  
118 increasing IFN-λ production (Fig. S3G). As expected, pro-inflammatory cytokines are expressed  
119 at low levels throughout the kinetic study (Fig. S3H, I). The correlation of bacterial burden with

120 IFN-λ protein kinetics suggests a causal relationship between IFN-λ production and susceptibility  
121 to superinfection. Indeed, administration of exogenous IFN-λ concomitantly with R848, which  
122 induces immune activation but not interferon production, was sufficient to induce sensitivity to *S.*  
123 *aureus* infection, increasing morbidity and bacterial burden (Fig. 1M, N). Overall, these data  
124 indicate that IFN-λ is sufficient to break the lung tolerance and induce susceptibility to subsequent  
125 bacterial infections.

126 Next, we examined if IFN-λ is not only sufficient but also necessary to establish morbidity  
127 and sensitize to bacterial superinfection upon viral exposure. Contrary to wild-type (WT) mice,  
128 mice deficient in interferon lambda receptor 1 expression (*Ifnrl1*<sup>-/-</sup> mice) are completely protected  
129 from poly (I:C) induced morbidity, both in terms of hypothermia induction and weight loss (Fig.  
130 2A, and Fig. S4A), and do not develop barrier damage (Fig. 2B, and Fig. S4B). Consistently with  
131 the absence of barrier defects, *Ifnrl1*<sup>-/-</sup> mice are completely protected from lethality upon *S. aureus*  
132 superinfection (Fig. 2C) and show lower bacterial burden (Fig. 2D), lower barrier damage and  
133 decreased hypothermic response (Fig. 2E, F) compared to WT mice. Deletion of IFNLR1 doesn't  
134 impact levels of mRNA or protein of IFNs or pro-inflammatory cytokines (Fig. S4C-H), confirming  
135 the direct role of IFN-λ in this context. Collectively these observations show that sustained  
136 expression of IFN-λ after RNA virus recognition is both necessary and sufficient to induce barrier  
137 breach and sensitization to *S. aureus* infection.

138 Our data demonstrate that IFN-λ alters the lung epithelial barrier function, but we and  
139 others also showed that this group of interferons downmodulates host immune resistance, by  
140 inhibiting ROS release, migration , and pro-inflammatory cytokine release by neutrophils(4–6), a  
141 key immune cell population involved in the response against lung viral infections(42, 43). Both  
142 decrease in barrier integrity(39, 40, 44), and decreased microbicidal activity of myeloid cells (45–  
143 47) are known to influence superinfection sensitivity. Therefore, we analyzed the relative  
144 contribution of IFN-λ to directly modulate immune functions and epithelial cell biology to the  
145 establishment of morbidity and *S. aureus* superinfection sensitivity in response to poly (I:C)

146 stimulation. To this end we generated reciprocal bone marrow chimeras in which either the  
147 hematopoietic compartment (*Ifnlr1*<sup>-/-</sup> → WT) or the stromal compartment (WT → *Ifnlr1*<sup>-/-</sup>) were  
148 defective for IFN-λ signaling, and the appropriate controls (*Ifnlr1*<sup>-/-</sup> → *Ifnlr1*<sup>-/-</sup>, WT → WT). WT →  
149 *Ifnlr1*<sup>-/-</sup> mice phenocopied complete *Ifnlr1*<sup>-/-</sup> → *Ifnlr1*<sup>-/-</sup> chimeras, displaying lower barrier damage  
150 before and after *S. aureus* infection (Fig. 2G, and Fig. S5), and decreased bacterial burden (Fig.  
151 2H). In contrast, *Ifnlr1*<sup>-/-</sup> → WT behaved like WT → WT mice (Fig. 2G, H). While IFN-λ may  
152 modulate immune function indirectly (71), we did not observe differences in myeloid immune cell  
153 recruitment in *Ifnlr1*<sup>-/-</sup> mice compared to WT (fig. S6A-D). Moreover, depletion of neutrophils did  
154 not impact bacterial burden under our experimental conditions (Fig. S6E), further supporting a  
155 direct role of IFN-λ on the epithelial barrier. Overall, these data demonstrate that IFN-λ signaling  
156 in epithelial cells is necessary and sufficient to impair lung tolerance, inducing barrier damage  
157 and susceptibility to a secondary infection.

158 In order to determine the molecular mechanisms elicited by IFN-λ in epithelial cells, we  
159 performed a targeted transcriptomic analysis on sorted epithelial cells from either WT or *Ifnlr1*<sup>-/-</sup>  
160 mice after poly (I:C) treatment (Fig. 3A, S7). Pathway analysis of  
161 differentially expressed genes (DEGs), revealed a potent downregulation of the IFN signature in  
162 *Ifnlr1*<sup>-/-</sup> compared to WT epithelial cells (Fig. 3B), confirming the predominant role of this group of  
163 IFNs compared to IFN-I during prolonged viral stimulation in the lung. Consistent with the  
164 observed defect in barrier function, genes associated with apoptosis and the activation of the p53  
165 pathway (Fig. 3B) were enriched in WT epithelial cells compared to *Ifnlr1*<sup>-/-</sup> (Fig. 3B), while  
166 pathways involved in positive regulation of the cell cycle were enriched in *Ifnlr1*<sup>-/-</sup> cells (Fig. 3C).  
167 Accordingly, epithelial cells in *Ifnlr1*<sup>-/-</sup> mice proliferate more efficiently after poly (I:C) administration  
168 (Fig. 3D) (as well as after *S. aureus* superinfection (Fig. 3E)) as measured by 5-Ethynyl-2'-  
169 deoxyuridine (EdU) incorporation, or expression of the proliferation marker Ki67 (Fig. 3F). In  
170 agreement with these data, epithelial cells in WT → *Ifnlr1*<sup>-/-</sup> chimeras also proliferate more

171 efficiently than mice that bear WT stromal cells, and phenocopy *Ifnlr1*<sup>-/-</sup> → *Ifnlr1*<sup>-/-</sup> chimeras (Fig.  
172 3G). These data further support the direct activity of IFN-λ on epithelial cells.

173 Interestingly, the gene that was most downregulated in *Ifnlr1*<sup>-/-</sup> epithelial cells compared to  
174 WT cells is the E3 ubiquitin-protein ligase makorin-1 (*Mrkn1*) (Fig. 3A),  
175 which controls p53 and p21 stability by favoring their proteasomal degradation (48). Under  
176 oxidative stress condition and DNA damage, a hallmark of severe viral infections (49), p53 is  
177 stabilized by phosphorylation and p21 degradation, mediated by *Mrkn1*, favors apoptosis over  
178 DNA repair (48). Indeed, *Ifnlr1*<sup>-/-</sup> epithelial cells, that express lower levels of *Mrkn1*, have elevated  
179 levels of p21 as measured by flow cytometry (Fig. 3H, I). These data indicate that the capacity of  
180 IFN-λ to reduce tissue tolerance stems from its capacity to inhibit tissue repair by directly  
181 influencing epithelial cell proliferation and viability. Also, that p21 degradation via *Mrkn1*  
182 upregulation is potently influenced by IFN-λ signaling.

183 RNA viruses can use several strategies to modulate the immune response to their  
184 advantage(33, 50), therefore it is crucial to understand the molecular pathways involved in the  
185 maintenance of sustained IFN-λ production. Moreover, the difference between mRNA expression  
186 and protein levels of interferons suggest that a low abundance cell type with high secretory  
187 capacity may be responsible for long term IFN-λ production. We thus investigated the cellular  
188 source and molecular pathways that drive IFN-λ production in our model. Early after initial  
189 influenza virus infection, IFN-λ is expressed by infected epithelial cells, however, at later time  
190 points, DCs from the parenchyma of the lung start to express high levels of the IFN-λ transcript(5).  
191 We thus hypothesized that lung DCs are the main producers of IFN-λ and are responsible for the  
192 secretion of IFN-λ during viral infections. Accordingly, sorted lung resident dendritic cells express  
193 high levels of IFN-λ transcript after 5 days of poly (I:C) treatment, in contrast to epithelial cells,  
194 alveolar macrophages and monocytes (Fig. 4A), which, instead, express IFN-I and pro-  
195 inflammatory cytokines (Fig. S8A, B). Moreover, diphtheria toxin (DT)-mediated depletion of  
196 CD11c<sup>+</sup> cells in CD11c-DT receptor (DTR) mice was sufficient to completely abolish IFN-λ

197 transcript and protein upregulation upon 6 days of poly (I:C) treatment (Fig. 4B, C), while IFN-I  
198 production remained unaltered (Fig. S8C, D). Having established that DCs are the main cell type  
199 involved in IFN-λ production, we analyzed the relevance of the three main RNA virus recognition  
200 pathways in the induction of IFN-λ in dendritic cells (i.e. TLR7-MyD88, RIG-I/MDA5-MAVS, TLR3-  
201 TRIF). We thus generated DCs from FMS-like tyrosine kinase 3 ligand (FLT3L)-derived bone  
202 marrow cell cultures (FLT3L-DCs). *In vitro* derived FLT3L-DCs comprise plasmacytoid DCs  
203 (pDCs), cDC1 and cDC2 like cells (53) and are well suited to model tissue DC responses *in vitro*.  
204 IFN-λ was induced only when the TLR3-TRIF pathway was activated by administering poly (I:C)  
205 in the supernatant, while neither stimulation of the RIG-I/MDA5-MAVS pathway by intracellular  
206 delivery of poly (I:C), nor stimulation of TLR7 were able to induce IFN-λ (Fig. 4D). Consistently  
207 with the response measured *in vivo*, TLR7 stimulation did not induce IFN production while it  
208 induced upregulation of pro-inflammatory cytokines, and intracellular delivery of poly (I:C) induced  
209 high levels of IFN-I but not IFN-λ (Fig. 4D, Fig. S9A, B). In agreement with the key role of TLR3,  
210 IFN-λ production upon extracellular poly (I:C) encounter was abolished by genetic deletion of the  
211 signaling adaptor TRIF (encoded by the gene *Ticam1*) but not by deletion of the RIG-I/MDA5  
212 adaptor MAVS (*Mavs*) (Fig. 4D). Conversely, IFN-I production in response to intracellular delivery  
213 of poly (I:C) was largely dependent on the signaling adaptor MAVS (Fig. S9A). Consistent with  
214 our previous data, when the RIG-I/MAVS pathway was activated by transfection of the influenza  
215 A virus derived pathogen-associated molecular pattern (PAMP) 3-phosphate-hairpin-RNA (3p-  
216 hpRNA), IFN-I but not IFN-λ, was efficiently induced in a MAVS-dependent manner (Fig. S10A-  
217 E, poly (I:C) was used as a control). Finally, inhibition of endosomal acidification by treatment with  
218 the pharmacological agent chloroquine abolished IFN-λ induction in response to extracellular poly  
219 (I:C), while it preserved IFN-I production upon intracellular poly (I:C) delivery (Fig. S11A, B).  
220 These evidences clearly indicate that TLR3 stimulation potently induces IFN-λ production by DCs  
221 *in vitro*. We, thus, explored the importance of the TLR3-TRIF pathway *in vivo* under our  
222 experimental conditions. Dendritic cells sorted from *Ticam1*<sup>-/-</sup> mice treated with poly (I:C) for six

223 days did not express appreciable levels of IFN-λ transcripts while still produced type I interferons  
224 (Fig. 4E, F). Moreover, poly (I:C) treated *Ticam1*<sup>-/-</sup> mice were protected from *S. aureus*  
225 superinfections (Fig. 4G), and the decrease in bacterial burden correlated with lower IFN-λ  
226 transcript levels in the lung, although IFN-I levels remained similar to those of WT mice (Fig. 4H,  
227 I). Confirming the crucial role of TLR3 signaling in DCs for IFN-λ production, chimeric mice in  
228 which *Ticam1*<sup>-/-</sup> bone marrow (BM) cells are transferred in a WT irradiated host (*Ticam1*<sup>-/-</sup>→WT)  
229 phenocopied *Ticam1*<sup>-/-</sup> animals (Fig. 4J-L).

230 The immune system evolved to prevent and resist to pathogen invasion but doing so often  
231 threatens host fitness and causes disease in the form of immunopathology (51). RNA viruses are  
232 the major cause of most severe lower respiratory tract viral infections (52, 53). While most virus  
233 infections manifest as self-limiting upper respiratory tract infections, influenza viruses, SARS-  
234 CoV, SARS-CoV-2 and MERS-CoV can progress to severe lung disease with potentially lethal  
235 outcomes(50, 54, 55). Although different viruses vary in their virulence and pathogenic potential,  
236 the most severe cases of lung RNA viral infections share similar features that suggest an immune  
237 pathological etiology. In COVID-19, SARS, MERS and flu, severe symptoms and death occur late  
238 after the initial symptoms onset, and after the peak in viral load (56–61) further indicating a central  
239 role for an immune etiology of the most severe forms.

240 While IFN-λ is uniquely equipped to induce a gentler immune response that favors viral  
241 clearance in the lungs without inducing overt immune activation (1, 3, 62), its impact on epithelial  
242 cell biology and its effect on the maintenance of tissue integrity and tolerance to pathogen invasion  
243 is incompletely understood. In a system that allowed us to isolate the effect of immune activation  
244 from resistance to viral infection, we demonstrate that sustained IFN-λ production in the lung in  
245 response to viral PAMPs compromises epithelial barrier function, induces lung pathology and  
246 morbidity and predisposes to lethal secondary infections by impairing the capacity of the lungs to  
247 tolerate bacterial invasion. Loss of lung barrier tolerance is sufficient to induce lethality upon  
248 bacterial challenge independently of bacterial growth (39), and alteration of the repair response

249 in the lung can favor bacterial invasion independently from immune cell control (63). In our model  
250 immune cell recruitment is not affected by IFN-λ and neutrophils are dispensable for the impaired  
251 control of bacterial infections, while IFN-λ signaling on epithelial cells is necessary and sufficient  
252 to cause heightened bacterial invasion.

253 Under our experimental conditions, TLR3-TRIF signaling in conventional lung DCs is  
254 responsible for the induction of IFN-λ. This is consistent with reports indicating that *Tlr3*-deficient  
255 mice are protected from influenza-induced immune pathology(64). Moreover, TLR3 detects  
256 replication intermediates from necrotic cells (35) and is, thus, insensitive to viral immune evasion.  
257 This is of particular interest during highly pathogenic human coronavirus infections, whose  
258 success in establishing the initial infection is partly due to their ability to dampen TLR7 and MAVS  
259 dependent early IFN responses(50), as indicated by their poor ability to induce IFN responses *in*  
260 *vitro* in epithelial cells (31). Indeed, severe clinical manifestations and surge of IFN and cytokine  
261 production are evident after the initial infection has peaked, as demonstrated by the analysis of  
262 the BAL of ICU-hospitalized COVID-19 patients.

263 IFN-λ has recently been proposed as a therapeutic agent for COVID-19 infections (13),  
264 and clinical trials have been initiated for mild and early SARS-CoV-2 infections (14) by virtue of  
265 its unique antiviral and immune modulatory activity. However, our discovery reveals not only that  
266 the most severe COVID-19 patients present high levels of type III IFNs in the lower airways, but  
267 also a previously unappreciated capacity of IFN-λ to interfere with repair processes, which renders  
268 treatment of severe COVID-19 patients with IFN-λ extremely dangerous. By contrast, existing  
269 clinical trials are exploring inhibition of the type II cytokine signaling adaptors Janus Kinases  
270 (JAKs) in severe COVID-19 patients (65). In light of our discoveries, inhibition of JAK kinases  
271 could be successful by both inhibiting detrimental activities of proinflammatory cytokines such as  
272 IL-6 and IFN-λ, and mitigating the antiproliferative effect of IFN-λ. Intriguingly, *in vitro* treatment of  
273 dendritic cells with chloroquine, a controversial therapeutic proposed against COVID-19(66–68),  
274 completely blocks TLR3-dependent IFN-λ production. Whether this inhibitory effect translates in

275 therapeutic settings, and whether it could have beneficial outcomes in COVID-19, remains an  
276 open question.

277 Collectively we demonstrate that sustained activation of antiviral immunity in the lungs  
278 induces the production over time of high levels of IFN- $\lambda$  by DCs through the TLR3-TRIF pathway.  
279 Prolonged IFN- $\lambda$  stimulation interferes with tissue repair by inhibiting epithelial cell proliferation  
280 and favoring p53 mediated apoptosis. This inhibitory effect toward barrier repair induced by IFN-  
281  $\lambda$  can drive immunopathogenesis in severe viral infections and predispose the host to impaired  
282 tolerance against opportunistic bacterial infections.

283

284 **References.**

- 285 1. H. M. Lazear, J. W. Schoggins, M. S. Diamond, Shared and Distinct Functions of Type I  
286 and Type III Interferons. *Immunity*. **50**, 907–923 (2019).
- 287 2. H. M. Lazear, T. J. Nice, M. S. Diamond, Interferon- $\lambda$ : Immune Functions at Barrier  
288 Surfaces and Beyond. *Immunity*. **43**, 15–28 (2015).
- 289 3. A. Broggi, F. Granucci, I. Zanoni, Type III interferons: Balancing tissue tolerance and  
290 resistance to pathogen invasion. *J. Exp. Med.* **217** (2020),  
291 doi:<https://doi.org/10.1084/jem.20190295>.
- 292 4. A. Broggi, Y. Tan, F. Granucci, I. Zanoni, IFN- $\lambda$  suppresses intestinal inflammation by non-  
293 translational regulation of neutrophil function. *Nat. Immunol.* **18**, 1084–1093 (2017).
- 294 5. I. E. Galani, V. Triantafyllia, E.-E. Eleminiadou, O. Koltsida, A. Stavropoulos, M.  
295 Manioudaki, D. Thanos, S. E. Doyle, S. V Kotenko, K. Thanopoulou, E. Andreakos,  
296 Interferon- $\lambda$  Mediates Non-redundant Front-Line Antiviral Protection against Influenza  
297 Virus Infection without Compromising Host Fitness. *Immunity*. **46**, 875–890.e6 (2017).
- 298 6. K. Blazek, H. L. Eames, M. Weiss, A. J. Byrne, D. Perocheau, J. E. Pease, S. Doyle, F.  
299 McCann, R. O. Williams, I. A. Udalova, IFN- $\lambda$  resolves inflammation via suppression of  
300 neutrophil infiltration and IL-1 $\beta$  production. *J. Exp. Med.* **212**, 845–853 (2015).

301 7. N. L.-S. Tang, P. K.-S. Chan, C.-K. Wong, K.-F. To, A. K.-L. Wu, Y.-M. Sung, D. S.-C. Hui,  
302 J. J.-Y. Sung, C. W.-K. Lam, Early Enhanced Expression of Interferon-Inducible Protein-  
303 10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute  
304 Respiratory Syndrome. *Clin. Chem.* **51**, 2333–2340 (2005).

305 8. J. S. M. Peiris, C. Y. Cheung, C. Y. H. Leung, J. M. Nicholls, Innate immune responses to  
306 influenza A H5N1: friend or foe? *Trends Immunol.* **30**, 574–584 (2009).

307 9. J. Sun, W.-T. He, L. Wang, A. Lai, X. Ji, X. Zhai, G. Li, M. A. Suchard, J. Tian, J. Zhou, M.  
308 Veit, S. Su, COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.  
309 *Trends Mol. Med.* (2020), doi:10.1016/j.molmed.2020.02.008.

310 10. Z. Zhou, L. Ren, L. Zhang, J. Zhong, Y. Xiao, Z. Jia, L. Guo, J. Yang, C. Wang, S. Jiang,  
311 D. Yang, G. Zhang, H. Li, F. Chen, Y. Xu, M. Chen, Z. Gao, J. Yang, J. Dong, B. Liu, X.  
312 Zhang, W. Wang, K. He, Q. Jin, M. Li, J. Wang, Overly Exuberant Innate Immune  
313 Response to SARS-CoV-2 Infection. *SSRN Electron. J.* (2020), doi:10.2139/ssrn.3551623.

314 11. G. Chen, D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang, H. Chen, H.  
315 Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S. Li, X. Luo, J. Zhao, Q. Ning,  
316 Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J.*  
317 *Clin. Invest.* (2020), doi:10.1172/jci137244.

318 12. J. Liu, X. Zheng, Q. Tong, W. Li, B. Wang, K. Sutter, M. Trilling, M. Lu, U. Dittmer, D. Yang,  
319 Overlapping and discrete aspects of the pathology and pathogenesis of the emerging  
320 human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J. Med. Virol.*  
321 **92**, 491–494 (2020).

322 13. L. Prokunina-Olsson, N. Alphonse, R. E. Dickenson, J. E. Durbin, J. S. Glenn, R. Hartmann,  
323 S. V Kotenko, H. M. Lazear, T. R. O'Brien, C. Odendall, O. O. Onabajo, H. Piontkivska, D.  
324 M. Santer, N. C. Reich, A. Wack, I. Zanoni, COVID-19 and emerging viral infections: The  
325 case for interferon lambda. *J. Exp. Med.* **217** (2020), doi:10.1084/jem.20200653.

326 14. S. U. Upinder Singh, A Phase 2 Randomized, Open Label Study of a Single Dose of

327 Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19  
328 (2020) (available at <https://clinicaltrials.gov/ct2/show/NCT04331899>).

329 15. J. A. McCullers, Insights into the Interaction between Influenza Virus and Pneumococcus.  
330 *Clin. Microbiol. Rev.* **19**, 571–582 (2006).

331 16. A. Rynda-Apple, K. M. Robinson, J. F. Alcorn, Influenza and Bacterial Superinfection:  
332 Illuminating the Immunologic Mechanisms of Disease. *Infect. Immun.* **83**, 3764–3770  
333 (2015).

334 17. P. S. Pillai, R. D. Molony, K. Martinod, H. Dong, I. K. Pang, M. C. Tal, A. G. Solis, P.  
335 Bielecki, S. Mohanty, M. Trentalange, R. J. Homer, R. A. Flavell, D. D. Wagner, R. R.  
336 Montgomery, A. C. Shaw, P. Staeheli, A. Iwasaki, Mx1 reveals innate pathways to antiviral  
337 resistance and lethal influenza disease. *Science*. **352**, 463–466 (2016).

338 18. H. E. Rich, C. C. McCourt, W. Q. Zheng, K. J. McHugh, K. M. Robinson, J. Wang, J. F.  
339 Alcorn, Interferon Lambda Inhibits Bacterial Uptake during Influenza Superinfection. *Infect.*  
340 *Immun.* **87** (2019), doi:10.1128/iai.00114-19.

341 19. P. J. Planet, D. Parker, T. S. Cohen, H. Smith, J. D. Leon, C. Ryan, T. J. Hammer, N.  
342 Fierer, E. I. Chen, A. S. Prince, Lambda Interferon Restructures the Nasal Microbiome and  
343 Increases Susceptibility to *Staphylococcus aureus* Superinfection. *MBio*. **7**, e01939–15  
344 (2016).

345 20. S. Pires, D. Parker, IL-1 $\beta$  activation in response to *Staphylococcus aureus* lung infection  
346 requires inflammasome-dependent and independent mechanisms. *Eur. J. Immunol.* **48**,  
347 1707–1716 (2018).

348 21. J. A. McCullers, The co-pathogenesis of influenza viruses with bacteria in the lung. *Nat.*  
349 *Rev. Microbiol.* **12**, 252–262 (2014).

350 22. Y. Liu, L. M. Yan, L. Wan, T. X. Xiang, A. Le, J. M. Liu, M. Peiris, L. L. M. Poon, W. Zhang,  
351 Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* **0** (2020),  
352 doi:10.1016/S1473-3099(20)30232-2.

353 23. Q. Xing, G. Li, Y. Xing, T. Chen, W. Li, W. Ni, K. Deng, R. Gao, C. Chen, Y. Gao, Q. Li, G.  
354 Yu, J. Tong, W. Li, G. Hao, Y. Sun, A. Zhang, Q. Wu, G. Ma, J. Cao, Z. Li, S. Pan, *medRxiv*,  
355 in press, doi:10.1101/2020.02.29.20027698.

356 24. S. Tian, Y. Xiong, H. Liu, L. Niu, J. Guo, M. Liao, S.-Y. Xiao, Pathological study of the 2019  
357 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod. Pathol.*,  
358 1–8 (2020).

359 25. R. Channappanavar, A. R. Fehr, R. Vijay, M. Mack, J. Zhao, D. K. Meyerholz, S. Perlman,  
360 Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses  
361 Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe*. **19**, 181–193  
362 (2016).

363 26. R. Channappanavar, S. Perlman, Pathogenic human coronavirus infections: causes and  
364 consequences of cytokine storm and immunopathology. *Semin. Immunopathol.* **39**, 529–  
365 539 (2017).

366 27. S. Crotta, S. Davidson, T. Mahlakoiv, C. J. Desmet, M. R. Buckwalter, M. L. Albert, P.  
367 Staeheli, A. Wack, Type I and Type III Interferons Drive Redundant Amplification Loops to  
368 Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia. *PLoS Pathog.* **9**,  
369 e1003773 (2013).

370 28. S. Davidson, S. Crotta, T. M. McCabe, A. Wack, Pathogenic potential of interferon  $\alpha\beta$  in  
371 acute influenza infection. *Nat. Commun.* **5**, 3864 (2014).

372 29. N. A. Jewell, T. Cline, S. E. Mertz, S. V Smirnov, E. Flaño, C. Schindler, J. L. Grieves, R.  
373 K. Durbin, S. V Kotenko, J. E. Durbin, Lambda Interferon Is the Predominant Interferon  
374 Induced by Influenza A Virus Infection In Vivo  $\triangleright$ . *J. Virol.* **84**, 11515–11522 (2010).

375 30. A. Pizzorno, B. Padey, T. Julien, S. Trouillet-Assant, A. Traversier, E. Errazuriz-Cerda, J.  
376 Fouret, J. Dubois, A. Gaymard, X. Lescure, V. Duliere, P. Brun, S. Constant, J. Poissy, B.  
377 Lina, Y. Yazdanpanah, O. Terrier, M. Rosa-Calatrava, *bioRxiv*, in press,

378 doi:10.1101/2020.03.31.017889.

379 31. D. Blanco-Melo, B. E. Nilsson-Payant, W.-C. Liu, S. Uhl, D. Hoagland, R. Møller, T. X.  
380 Jordan, K. Oishi, M. Panis, D. Sachs, T. T. Wang, R. E. Schwartz, J. K. Lim, R. A. Albrecht,  
381 B. R. Tenover, Journal pre-proof Imbalanced host response to SARS-CoV-2 drives  
382 development of COVID-19 (2020), doi:10.1016/j.cell.2020.04.026.

383 32. I. K. Pang, A. Iwasaki, Control of antiviral immunity by pattern recognition and the  
384 microbiome. *Immunol. Rev.* **245**, 209–226 (2012).

385 33. A. Iwasaki, P. S. Pillai, Innate immunity to influenza virus infection. *Nat. Rev. Immunol.* **14**,  
386 315–328 (2014).

387 34. S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, C. R. e Sousa, Innate Antiviral Responses  
388 by Means of TLR7-Mediated Recognition of Single-Stranded RNA. *Science* (80- ). **303**,  
389 1529–1531 (2004).

390 35. O. Schulz, S. S. Diebold, M. Chen, T. I. Näslund, M. A. Nolte, L. Alexopoulou, Y.-T. Azuma,  
391 R. A. Flavell, P. Liljeström, C. R. e Sousa, Toll-like receptor 3 promotes cross-priming to  
392 virus-infected cells. *Nature*. **433**, 887–892 (2005).

393 36. S. McCartney, W. Vermi, S. Gilfillan, M. Cella, T. L. Murphy, R. D. Schreiber, K. M. Murphy,  
394 M. Colonna, Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-  
395 mediated activation of mouse NK cells. *J. Exp. Med.* **206**, 2967–2976 (2009).

396 37. H. Kato, O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A.  
397 Jung, T. Kawai, K. J. Ishii, O. Yamaguchi, K. Otsu, T. Tsujimura, C.-S. Koh, C. R. e Sousa,  
398 Y. Matsuura, T. Fujita, S. Akira, Differential roles of MDA5 and RIG-I helicases in the  
399 recognition of RNA viruses. *Nature*. **441**, 101–105 (2006).

400 38. S. Ivanov, J. Renneson, J. Fontaine, A. Barthelemy, C. Paget, E. M. Fernandez, F. Blanc,  
401 C. De Trez, L. Van Maele, L. Dumoutier, M.-R. Huerre, G. Eberl, M. Si-Tahar, P. Gosset,  
402 J. C. Renauld, J. C. Sirard, C. Faveeuw, F. Trottein, Interleukin-22 Reduces Lung  
403 Inflammation during Influenza A Virus Infection and Protects against Secondary Bacterial

404 Infection. *J. Virol.* **87**, 6911–6924 (2013).

405 39. A. M. Jamieson, L. Pasman, S. Yu, P. Gamradt, R. J. Homer, T. Decker, R. Medzhitov,  
406 Role of Tissue Protection in Lethal Respiratory Viral-Bacterial Coinfection. *Science* (80- ).  
407 **340**, 1230–1234 (2013).

408 40. R. N. Abood, K. J. McHugh, H. E. Rich, M. A. Ortiz, J. M. Tobin, K. Ramanan, K. M.  
409 Robinson, J. M. Bomberger, J. K. Kolls, M. L. Manni, D. A. Pociask, J. F. Alcorn, IL-22-  
410 binding protein exacerbates influenza, bacterial super-infection. *Mucosal Immunol.* **12**,  
411 1231–1243 (2019).

412 41. A. Forero, S. Ozarkar, H. Li, C. H. Lee, E. A. Hemann, M. S. Nadjsombati, M. R. Hendricks,  
413 L. So, R. Green, C. N. Roy, S. N. Sarkar, J. von Moltke, S. K. Anderson, M. Gale, R. Savan,  
414 Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune  
415 Responses Elicited by Type I and Type III Interferons. *Immunity*. **51**, 451–464.e6 (2019).

416 42. M. Brandes, F. Klauschen, S. Kuchen, R. N. Germain, A systems analysis identifies a  
417 feedforward inflammatory circuit leading to lethal influenza infection. *Cell*. **154**, 197–212  
418 (2013).

419 43. I. E. Galani, E. Andreakos, Neutrophils in viral infections: Current concepts and caveats. *J.*  
420 *Leukoc. Biol.* **98**, 557–564 (2015).

421 44. K. M. Robinson, S. M. Choi, K. J. McHugh, S. Mandalapu, R. I. Enelow, J. K. Kolls, J. F.  
422 Alcorn, Influenza A Exacerbates *Staphylococcus aureus* Pneumonia by Attenuating IL-1 $\beta$   
423 Production in Mice. *J. Immunol.* **191**, 5153–5159 (2013).

424 45. K. Sun, D. W. Metzger, Inhibition of pulmonary antibacterial defense by interferon-gamma  
425 during recovery from influenza infection. *Nat. Med.* **14**, 558–564 (2008).

426 46. K. Sun, D. W. Metzger, Influenza infection suppresses NADPH oxidase-dependent  
427 phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-  
428 resistant *Staphylococcus aureus* infection. *J. Immunol.* **192**, 3301–3307 (2014).

429 47. H. E. Ghoneim, P. G. Thomas, J. A. McCullers, Depletion of Alveolar Macrophages during

430                   Influenza Infection Facilitates Bacterial Superinfections. *J. Immunol.* **191**, 1250–1259

431                   (2013).

432   48. E.-W. Lee, M.-S. Lee, S. Camus, J. Ghim, M.-R. Yang, W. Oh, N.-C. Ha, D. P. Lane, J.

433                   Song, Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest

434                   and apoptosis. *EMBO J.* **28**, 2100–2113 (2009).

435   49. N. Li, M. Parrish, T. K. Chan, L. Yin, P. Rai, Y. Yoshiyuki, N. Abolhassani, K. B. Tan, O.

436                   Kiraly, V. T. K. Chow, B. P. Engelward, Influenza infection induces host DNA damage and

437                   dynamic DNA damage responses during tissue regeneration. *Cell. Mol. Life Sci.* **72**, 2973–

438                   2988 (2015).

439   50. E. de Wit, N. van Doremalen, D. Falzarano, V. J. Munster, SARS and MERS: recent

440                   insights into emerging coronaviruses. *Nat. Rev. Microbiol.* **14**, 523–534 (2016).

441   51. R. Medzhitov, D. S. Schneider, M. P. Soares, Disease tolerance as a defense strategy.

442                   *Science*. **335**, 936–941 (2012).

443   52. W. G. Nichols, A. J. P. Campbell, M. Boeckh, Respiratory viruses other than influenza virus:

444                   impact and therapeutic advances. *Clin. Microbiol. Rev.* **21**, 274–90, table of contents

445                   (2008).

446   53. A. T. Pavia, Viral infections of the lower respiratory tract: old viruses, new viruses, and the

447                   role of diagnosis. *Clin. Infect. Dis.* **52 Suppl 4**, S284–9 (2011).

448   54. Z. A. Memish, S. Perlman, M. D. Van Kerkhove, A. Zumla, Middle East respiratory

449                   syndrome. *Lancet*. **395** (2020), pp. 1063–1077.

450   55. F. Krammer, G. J. D. Smith, R. A. M. Fouchier, M. Peiris, K. Kedzierska, P. C. Doherty, P.

451                   Palese, M. L. Shaw, J. Treanor, R. G. Webster, A. García-Sastre, Influenza. *Nat. Rev. Dis.*

452                   *Prim.* **4**, 3 (2018).

453   56. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-Dannenburg,

454                   H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M. Baguelin, S. Bhatia, A.

455                   Boonyasiri, A. Cori, Z. Cucunubá, R. FitzJohn, K. Gaythorpe, W. Green, A. Hamlet, W.

456 Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van Elsland, E. Volz, H. Wang, Y. Wang,  
457 X. Xi, C. A. Donnelly, A. C. Ghani, N. M. Ferguson, Estimates of the severity of coronavirus  
458 disease 2019: a model-based analysis. *Lancet Infect. Dis.* **0** (2020), doi:10.1016/s1473-  
459 3099(20)30243-7.

460 57. J. S. M. Peiris, C. M. Chu, V. C. C. Cheng, K. S. Chan, I. F. N. Hung, L. L. M. Poon, K. I.  
461 Law, B. S. F. Tang, T. Y. W. Hon, C. S. Chan, K. H. Chan, J. S. C. Ng, B. J. Zheng, W. L.  
462 Ng, R. W. M. Lai, Y. Guan, K. Y. Yuen, Clinical progression and viral load in a community  
463 outbreak of coronavirus-associated SARS pneumonia: A prospective study. *Lancet.* **361**,  
464 1767–1772 (2003).

465 58. W. Wang, S. Chen, I. -Jung Liu, C. Kao, H. Chen, B. Chiang, J. Wang, W. Sheng, P. Hsueh,  
466 C. Yang, P. Yang, S. Chang, S. A. R. S. R. G. of the N. T. U. (NTU) C. of M. Hospital,  
467 Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical  
468 Progression in Patients with Severe Acute Respiratory Syndrome. *Clin. Infect. Dis.* **39**,  
469 1071–1075 (2004).

470 59. R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmäier, S. Zange, M. A. Müller, D.  
471 Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J.  
472 Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment  
473 of hospitalized patients with COVID-2019. *Nature*, 1–10 (2020).

474 60. A. Granados, A. Peci, A. McGeer, J. B. Gubbay, Influenza and rhinovirus viral load and  
475 disease severity in upper respiratory tract infections. *J. Clin. Virol.* **86**, 14–19 (2017).

476 61. M. J. Cameron, L. Ran, L. Xu, A. Danesh, J. F. Bermejo-Martin, C. M. Cameron, M. P.  
477 Muller, W. L. Gold, S. E. Richardson, S. M. Poutanen, B. M. Willey, M. E. DeVries, Y. Fang,  
478 C. Seneviratne, S. E. Bosinger, D. Persad, P. Wilkinson, L. D. Greller, R. Somogyi, A.  
479 Humar, S. Keshavjee, M. Louie, M. B. Loeb, J. Brunton, A. J. McGeer, C. S. R. Network,  
480 D. J. Kelvin, Interferon-Mediated Immunopathological Events Are Associated with Atypical  
481 Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory

482 Syndrome. *J. Virol.* **81**, 8692–8706 (2007).

483 62. L. Ye, D. Schnepf, P. Staeheli, Interferon-λ orchestrates innate and adaptive mucosal  
484 immune responses. *Nat. Rev. Immunol.* **19**, 614–625 (2019).

485 63. D. Ahn, M. Wickersham, S. Riquelme, A. Prince, The Effects of IFN-λ on Epithelial Barrier  
486 Function Contribute to *Klebsiella pneumoniae* ST258 Pneumonia. *Am. J. Respir. Cell Mol.*  
487 *Biol.* **60**, 158–166 (2019).

488 64. R. Le Goffic, V. Balloy, M. Lagranderie, L. Alexopoulou, N. Escriou, R. Flavell, M. Chignard,  
489 M. Si-Tahar, Detrimental Contribution of the Toll-Like Receptor (TLR)3 to Influenza A  
490 Virus–Induced Acute Pneumonia. *PLoS Pathog.* **2**, e53 (2006).

491 65. Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. -  
492 Full Text View - ClinicalTrials.gov, (available at  
493 <https://www.clinicaltrials.gov/ct2/show/NCT04320277>).

494 66. P. Gautret, J.-C. Lagier, P. Parola, V. T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J.  
495 Courjon, V. Giordanengo, V. E. Vieira, H. T. Dupont, S. Honoré, P. Colson, E. Chabrière,  
496 B. La Scola, J.-M. Rolain, P. Brouqui, D. Raoult, Hydroxychloroquine and azithromycin as  
497 a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int. J.*  
498 *Antimicrob. Agents*, 105949 (2020).

499 67. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao,  
500 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus  
501 (2019-nCoV) in vitro. *Cell Res.* **30**, 269–271 (2020).

502 68. F. Touret, X. de Lamballerie, Of chloroquine and COVID-19. *Antiviral Res.* **177**, 104762  
503 (2020).

504


## 505 Acknowledgments.

506 We thank Dr. JC Kagan for discussion, help and support. **Funding:** IZ is supported by NIH grant  
507 1R01AI121066, 1R01DK115217, and NIAID-DAIT-NIHA1201700100. AB is supported by CCFA

508 RFA 549868. FG is supported by AIRC (IG 2019Id.23512), Fondazione regionale per la ricerca  
509 biomedica, FRRB (IANG-CRC - CP2\_12/2018), and Ministero della Salute, Ricerca Finalizzata  
510 (RF-2018-12367072). **Authors contributions:** AB, SG, and BS designed, performed, and  
511 analyzed the experiments; AB wrote the paper; RS performed the analysis of the sequencing  
512 data; FB and ALC performed the experiments; NC, MDS, and NM performed and analyzed human  
513 experiments; FG contributed to the design of the experiments; IZ conceived the project, designed  
514 the experiments, supervised the study and wrote the paper. **Competing interests:** The authors  
515 declare no commercial or financial conflict of interest. **Data and materials availability:** all data  
516 is available in the manuscript or the supplementary materials and/or upon request to the  
517 corresponding author.

518

519




520

521 **Figure 1. Morbidity correlates with the high expression of IFN-I and IFN-λ in the lung of**  
 522 **COVID-19 patients' BAL and of poly (I:C)-treated mice.** (A-E) mRNA expression of *IFNL2,3*,  
 523 *IFNL1* (A), *IFNB* (B), *IFNA2* (C), *IL1B* (D), and *IL6* (E) were evaluated in naso-oropharyngeal  
 524 swabs from SARS-CoV-2-positive (Swab CoV+) and -negative (Swab CoV-) subjects and from  
 525 bronchoalveolar lavages of intensive care unit (ICU)-hospitalized SARS-CoV-2-positive patients  
 526 (BAL CoV+). (F-J) Mice were treated daily with i.t. 0.5 mg/kg poly (I:C), 0.5 mg/kg R848 or saline  
 527 for 6 days. (F) Body temperatures of the treated mice measured over time are represented. (G)  
 528 Amount of total protein in the BAL was measured at day 6 post treatment. (H-J) *Ifnl2,3* (H), *Ifnb1*

529 (I), *Il1b* (J) mRNA expression was assessed in total lung lysate harvested 6 days post treatment.  
530 (K, L) Mice treated as in (F-J) were infected at day 6 with  $0.5 \times 10^8$  CFU of *S. aureus* administered  
531 i.t. and were monitored for survival (K). Bacterial load in the lungs of the treated mice normalized  
532 to lung weight was assessed 12 hours post infection (hpi) (L). Mice were administered daily i.t.  
533 R848 (0.5 mg/kg) or a combination of R848 and IFN- $\lambda$  (50 $\mu$ g/kg) for 6 days and were then infected  
534 as in (K). Bacterial burden in the lungs (M) and body temperatures (N) before and after *S. aureus*  
535 infection are depicted. (G-J, L-N) Each symbol represents one mouse, median and range are  
536 represented. (F) Mean and SEM of 5 mice per group is represented. (K) Survival plot of 5 mice  
537 per group. (F-N) Representative data of 3 independent experiments.  
538 Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$ . Two-way ANOVA  
539 (F, N), One-way ANOVA (G-J, L), or two-tailed T test (M) were performed. Logarithmic values  
540 were fitted when evaluating bacterial load (L, M). Log-rank (Mantel-Cox) test, corrected for  
541 multiple comparisons was performed to evaluate survival (K).

542




543

544 **Figure 2. IFN-λ is necessary to increase susceptibility to bacterial infection induced by**  
 545 **antiviral immunity.** (A, B) WT and *Ifnlr1*<sup>⁻/⁻</sup> mice were treated daily with 0.5 mg/kg poly (I:C) or  
 546 saline for 6 days. (A) Body temperatures of poly (I:C)-treated WT and *Ifnlr1*<sup>⁻/⁻</sup> mice were recorded  
 547 on day 6. (B) On day 6 mice were treated i.t. with FITC-Dextran (10µg/mouse). Barrier  
 548 permeability was measured as relative fluorescent units (RFU) of FITC-Dextran leaked in plasma  
 549 1 hour after injection. (C-F) WT and *Ifnlr1*<sup>⁻/⁻</sup> mice treated with i.t. 0.5 mg/kg poly (I:C) or saline for  
 550 6 days, were infected i.t. with  $0.5 \times 10^6$  CFU of *S. aureus* and monitored for survival (C). Lung  
 551 bacterial burden normalized by lung weight (D), body temperature (E), and barrier permeability  
 552 (F) (as in (B)) were assessed 12 hpi. (G-H) Lethally irradiated WT or *Ifnlr1*<sup>⁻/⁻</sup> recipients were  
 553 reconstituted with donor bone marrow (*Ifnlr1*<sup>⁻/⁻</sup> or WT) for 6 weeks and were treated as in (C-F).  
 554 (G) Barrier permeability measured (as in (B)) and (H) lung bacterial burdens were evaluated 12  
 555 hpi. Each symbol represents one mouse, median and range are represented. (C) Survival plot of  
 556 5 mice per group. (A-H) Representative data of 3 independent experiments. Statistics: ns, not  
 557 significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$ . Two-way ANOVA (B, D, F, H)),

558 One-way ANOVA (G), or two-tailed T test (A, E) were performed. Logarithmic values were fitted  
559 when evaluating bacterial load (D, H). Log-rank (Mantel-Cox) test, corrected for multiple  
560 comparisons was performed to evaluate survival (C).

561




562

563 **Figure 3. IFN-λ signaling directly inhibits lung epithelia proliferation and impairs repair**

564 **upon viral recognition.** (A-C) Targeted transcriptome sequencing was performed on lung

565 epithelial cells isolated on day 6 from WT and *Ifnlr1*<sup>-/-</sup> mice treated daily with i.t. 0.5 mg/kg poly  
566 (I:C) for 6 days. (A) Volcano plot of differentially expressed genes (DEGs) between WT and *Ifnlr1*<sup>-/-</sup>.  
567 DEGs (p-value < 0.005) with a Fold Change > 1.5 (or < -1.5) are indicated in red. Non-significant  
568 DEGs (P-value > 0.005) are indicated in green. (B-C) Dot Plot visualization of Gene Set  
569 Enrichment Analysis (GSEA) for pathways enriched in (B) WT epithelial cells compared to *Ifnlr1*<sup>-/-</sup>  
570 and (C) *Ifnlr1*<sup>-/-</sup> epithelial cells compared to WT. The color of the dots represents the adjusted p-  
571 value (Significance) for each enriched pathway and its size represents the percentage of genes  
572 enriched in the total gene set. (D, E) Epithelial cell proliferation was assessed as EdU  
573 incorporation in lung epithelial cells (CD45<sup>-</sup>CD31<sup>-</sup>EPCAM<sup>+</sup>) in WT and *Ifnlr1*<sup>-/-</sup> mice treated as in  
574 (A-C) (D) or treated as in (A-C) and infected on day 6 i.t. with 0.5 x 10<sup>8</sup> CFU *S. aureus* for 12h  
575 (E). (F) Mean fluorescent Intensity (MFI) of Ki67 in CD45 CD31<sup>-</sup>EPCAM<sup>+</sup> cells of WT and *Ifnlr1*<sup>-/-</sup>  
576 mice treated as in (A-C). (G) EdU incorporation in lung epithelial cells of WT or *Ifnlr1*<sup>-/-</sup> chimeric  
577 mice reconstituted with *Ifnlr1*<sup>-/-</sup> or WT bone marrow treated as in (E). (H, I) p21 levels in lung  
578 epithelial cells (CD45<sup>-</sup> CD31<sup>-</sup> EPCAM<sup>+</sup>) from WT and *Ifnlr1*<sup>-/-</sup> mice treated as in (A-C).  
579 Representative histogram (H) and MFI (I) are depicted.  
580 (A-C) 4 mice per genotype. (D-I) Each symbol represents one mouse. (D-I) Representative data  
581 of 3 independent experiments. Statistics: ns, not significant (P > 0.05); \*P < 0.05, \*\*P < 0.01 and  
582 \*\*\*P < 0.001. (D, E) Two-way ANOVA, (G) One-way ANOVA, (F, I), and two-tailed t test (I) were  
583 performed.



584

585 **Figure 4. Lung resident DCs produce IFN-λ in a TRIF-dependent manner upon viral**  
 586 **recognition. (A)** *Ifn1/2,3* relative mRNA expression in sorted lung epithelial cells (EC), resident DC  
 587 (resDC), monocytes and monocyte-derived cells (Mo) and alveolar macrophages (aMac) sorted  
 588 from WT mice treated daily with i.t. 0.5 mg/kg poly (I:C) or saline for 6 days was measured on day  
 589 6. (B) CD11c-DTR mice were injected with diphtheria toxin (DTx) to deplete the CD11c<sup>+</sup> cells *in*

590 *vivo*. Relative *Ifnl2,3* mRNA (B) and IFN-λ protein levels (C) from lung homogenates were  
591 evaluated on day 6. (D) FLT3-DCs from WT, *Ticam1*<sup>-/-</sup> or *Mavs*<sup>-/-</sup> mice were treated with 50µg/ml  
592 poly (I:C), 1µg/ml transfected poly (I:C) or 50µg/ml R848 for 3h. Relative *Ifnl2,3* mRNA expression  
593 was evaluated by qPCR. *Ifnl2,3* (E) and *Ifnb1* (F) relative mRNA expression in sorted lung  
594 epithelial cells (EC), resident DC (resDC), and monocytes and monocyte derived cells (Mo) sorted  
595 from WT and *Ticam1*<sup>-/-</sup> mice treated as in (A) was measured on day 6. (G-I) WT and *Ticam1*<sup>-/-</sup>  
596 mice were treated with poly (I:C) as in (A) and subsequently infected with i.t. 0.5 x 10<sup>8</sup> CFU of *S.*  
597 *aureus* on day 6 for 12h. Lung bacterial burden normalized by lung weight (G), *Ifnl2,3* (H) and  
598 *Ifnb1* (I) relative mRNA expressions were evaluated. (J-I) WT chimeric mice reconstituted with  
599 *Ticam1*<sup>-/-</sup> bone marrow (*Ticam1*->WT) or WT bone marrow (WT->WT) were treated as in (G-I).  
600 Lung bacterial burden normalized by lung weight (J), *Ifnl2,3* (K) and *Ifnb1* (L) relative mRNA  
601 expressions 12 hpi were evaluated. Representative data of 3 independent experiments.  
602 Statistics: ns, not significant (P > 0.05); \*P < 0.05, \*\*P < 0.01 and \*\*\*P < 0.001 (Two-way ANOVA).  
603 (G-L) Each dot represents one mouse. Median and range are depicted. (A-F) Mean and SEM of  
604 4 mice (A-C, E, F) and of 3 independent experiments (D) are depicted.

605  
606  
607  
608  
609  
610  
611

## Materials and Methods

### Mice

C57BL/6J (Jax 00664) (wild-type; WT), B6.SJL-Ptprca Pepcb/BoyJ (CD45.1; Jax 002014), C57BL/6J-*Ticam1*<sup>Lps2</sup>/J (*Ticam1*<sup>-/-</sup>; Jax 005037), B6;129-*Mavs*<sup>tm1Zjc</sup>/J (*Mavs*<sup>-/-</sup>; Jax 008634), B6.FVB-1700016L21RikTg(*Itgax*-DTR/EGFP)57Lan/J (CD11c-DTR, Jax 004509) mice were purchased from Jackson Labs. C57BL/6 IL-28R<sup>-/-</sup> (*Ifnlr1*<sup>-/-</sup>) mice were provided by Bristol-Myers Squibb. Mice were housed under specific pathogen-free conditions at Boston Children's Hospital. *Staphylococcus aureus* infections were conducted in the Biosafety Level-2 facility at Boston Children's Hospital. All procedures were approved under the Institutional Animal Care and Use Committee (IACUC) and conducted under the supervision of the department of Animal Resources at Children's Hospital (ARCH).

### Reagents and antibodies

Antibodies used for flow cytometry and sorting experiments: CD45.1 (A20), CD45.2 (104), total CD45 (30-F11), EpCAM (G8.8), CD31 (MEC13.3), CD24 (M1/69), MHC-II I-A/I-E (M5/114.15.2), Ly6G (1A8), Ly6C (HK1.4), CD11b (M1/70), CD11c (N418), CD64 (X54-5/71), Siglec F (S17007L), CD3 (45.2C11), CD19 (6D5), erythroid cell marker (Ter119), Ki67 (16A8), purchased from Biolegend; p21 (F-5) purchased from Santa Cruz. Live/dead cell markers Zombie Red™ (423109) or Zombie Violet™ (423113) dyes were purchased from Biolegend.

For *in vitro* and/or *in vivo* studies, poly (I:C) HMW (tlr-pic), R848 (tlr-r848) and 3p-hpRNA (tlrl-hprna) were purchased from Invivogen. For *in vivo* administration of type III IFN, we used polyethylene glycol-conjugated IFN-λ2 (PEG-IFN-λ) (gift from Bristol-Myers Squibb). Diphtheria toxin (unnickled) from *Corynebacterium diphtheriae* was purchased from Cayman Chemical. Anti-Ly6G antibody, clone 1A8 (BE0075-1) and rat IgG2a isotype control (BE0089) for *in vivo* administration was purchased from Bioxcell. 2'-Deoxy-5-ethynyl uridine (EdU) was purchased from Carbosynth (NE08701). Chloroquine (PHR1258), Fluorescein isothiocyanate (FITC)-

Dextran (MW:10,000da) (FD10S), Deoxyribonuclease (DNase) I from bovine pancreas (DN25) and Dispase II (D4693) were purchased from MilliporeSigma.

### ***In vivo treatments and infection***

Intratracheal instillations (i.t.) were performed as previously described in (69) 0.5mg/kg of poly (I:C) HMW, R848 or saline were administered i.t. daily for 6 days or as indicated in the figure legends. Where indicated, mice were treated i.t. with recombinant 50 $\mu$ g/kg PEG-IFN- $\lambda$  concomitantly from day 2 post-treatment, with R848 stimulation. *Staphylococcus aureus* subsp. *aureus* Rosenbach (ATCC® 25904™) was grown at 37°C in Tryptic Soy Broth (TSB) for 16h to the autolytic phase, then subcultured and grown to an optical density (OD<sub>600</sub>) of 0.4, centrifuged and resuspended in PBS immediately prior to infection. Each mouse was infected by i.t. instillation of 0.5 x 10<sup>8</sup> CFU of *S. aureus* and sacrificed 12 hours post-infection, except for in survival studies. Rectal temperature and body weights were monitored daily.

### **Survival study and endpoints**

Mice were deemed to have reached endpoint at 75% of starting weight or after reaching body temperature of 25°C or lower.

### **Generation of bone-marrow chimeras**

To generate mice with hematopoietic-specific deletion of *Ifnlr1* or *Ticam1*, 6-week-old CD45.1+ mice were exposed to lethal whole-body irradiation (950 rads per mouse) and were reconstituted with 5 x 10<sup>6</sup> donor bone marrow cells from 6-week-old wild-type, *Ifnlr1*<sup>-/-</sup> or *Ticam1*<sup>-/-</sup> mice. Mice were treated with sulfatrim in the drinking water and kept in autoclaved cages for 2 weeks after reconstitution. After 2 weeks, mice were placed in cages with mixed bedding from wild-type, and *Ifnlr1*<sup>-/-</sup> or *Ticam1*<sup>-/-</sup> mice to replenish the microbiome and were allowed to reconstitute for 2 more

weeks. A similar procedure was used to generate bone-marrow chimeras with stromal cell-specific deletion in *Ifnlr1*. Here, recipient WT or *Ifnlr1*<sup>-/-</sup> mice underwent irradiation and were reconstituted with BM cells derived from CD45.1+ mice similarly as described above.

To evaluate the percentage of chimerism, a sample of peripheral blood was taken from chimeric mice after 4 weeks of reconstitution and stained for CD45.1 and CD45.2 (antibodies as identified under 'Reagents and antibodies') and were analyzed by flow cytometry.

### **Depletion of Dendritic cells and Neutrophils**

In order to deplete CD11c<sup>+</sup> cells, CD11c-DTR mice received 16 $\mu$ g/kg diphtheria toxin (DTx) intravenously starting one day before TLR ligand or saline administration and continuing every other day until day 6 post-treatment to maintain depletion.

*In vivo* depletion of neutrophils was carried out by injecting anti-Ly6G antibody (100 $\mu$ g/mouse) intraperitoneally, starting one day before treatments and then continuing every other day through the duration of the treatment. As controls for no depletion, mice were injected with rat IgG isotype control.

### **Barrier permeability assessment**

To assess lung permeability, treated mice were administered FITC-dextran (10 $\mu$ g/mouse) i.t. before or after *S. aureus* infection. After 1hr of dextran instillation, blood was collected from the retro-orbital sinus, and the plasma was separated by centrifugation. Leakage of dextran in the bloodstream was measured as FITC fluorescence in the plasma compared to plasma from mock-treated mice.

### **Bronchoalveolar lavage (BAL) and lung collection.**

BAL was collected as described in (70) Briefly, the lungs of euthanized mice were lavaged through the trachea with 3ml PBS to collect the BAL. Samples were centrifuged and the supernatants

were used for total protein measurement (Pierce BCA Protein Assay, Thermo Fisher Scientific #23227) and LDH quantification (Pierce LDH Cytotoxicity Assay, Thermo Fisher Scientific #C20301). Lungs were excised and used for RNA extraction using TRI Reagent (Zymo Research #R2050-1-200).

### **Bacterial load and lung cytokine production measurement**

The left lobe of the lung was weighed and homogenized in 1ml of sterile D.I. water in a Fisherbrand™ Bead Mill 24 Homogenizer. To calculate bacterial load, homogenate was serially diluted and plated on TSB-Agar plates in duplicate. Colonies were counted after 16h incubation, and bacterial burden in the lungs was calculated as CFU normalized to individual lung weight. Cytokines production in the lungs was measured in the supernatants collected after centrifuging the lung homogenates.

### **Flow cytometry and cell sorting**

Lung cells were isolated as described in (71) Briefly, mice were euthanized and perfused. 2 ml of warm dispase solution (5mg/ml) were instilled into the lungs followed by 0.5ml of 1% low-melt agarose (Sigma #A9414) at 40°C, and allowed to solidify on ice. Inflated lungs were incubated in dispase solution, for 30' at RT. The lungs were then physically dissociated, incubated 10' with DNase I 50 µg/ml and filtered through 100µm and 70µm strainers. Red blood cells were lysed using ACK buffer. Single cell suspensions were stained for live/dead using Zombie Red or Zombie Violet, and then with antibodies against surface antigens diluted in PBS + BSA 0.2% for 20 minutes at 4°C. Cells were then washed, fixed with 3.7% paraformaldehyde for 10 minutes at room temperature, washed again and resuspended in PBS + BSA 0.2%. Samples were acquired on a BD LSRII flow cytometer and data were analyzed using FlowJo v.10 software (BD Biosciences). CountBright Absolute Counting Beads (Invitrogen #C36950) were used to quantify absolute cell numbers.

For cell sorting, FACS samples were prepared as described above, and sorted on Sony MA900 Cell Sorter following the sorting strategy indicated in Fig. S12. The sorted cells were collected directly into TRI Reagent for RNA extraction. For detecting cell proliferation, fixed cells were treated to assess for 5-Ethynyl-2'-deoxyuridine (EdU) incorporation as described below ('Epithelial cell proliferation') before being stained with antibodies against cell-surface antigens. Intracellular staining of Ki67 and p21 were carried out using FoxP3 Fix/Perm Buffer set (Biolegend #421403) following the manufacturer's instructions.

### **Epithelial cell proliferation**

Proliferation of lung epithelial cells was monitored by assessing the incorporation of EdU (100 mg/kg, intraperitoneally, 12h before end-point euthanasia), and analyzed by flow cytometry or histology. Briefly, single cell suspensions of lung cells from mice injected with EdU were isolated as described before ('Flow cytometry and cell sorting'). Single cell suspensions were assessed for live/dead and fixed using 3.7% PFA. Staining for EdU was carried out by Click-chemistry reaction. Fixed cells were permeabilized with 0.1% Triton X100 (Millipore-Sigma) for 15 min. After permeabilization cells were washed and incubated with 4 mM Copper sulphate (Millipore-Sigma), 100 mM Sodium ascorbate (Millipore-Sigma) and 5 µM sulfo-Cyanine3-azide (Lumiprobe #A1330) in Tris Buffered Saline (TBS) 100mM, pH 7.6, for 30 min at room temperature.

### **Ion Torrent**

For targeted transcriptome sequencing, 20 ng of RNA isolated from sorted cells was retro-transcribed to cDNA using SuperScript VILO cDNA Synthesis Kit (ThermoFisher Scientific). Barcoded libraries were prepared using the Ion AmpliSeq Transcriptome Mouse Gene Expression Kit as per the manufacturer's protocol and sequenced using an Ion S5 system (ThermoFisher Scientific). Differential gene expression analysis was performed using the Transcriptome Analysis Console (TAC) software with the ampliSeqRNA plugin (ThermoFisher Scientific).

Genes were called expressed (n=11,294) if they had average  $\log_2$  expression of 2 or greater in either WT or *Ifnlr1*<sup>-/-</sup>. Differentially expressed genes (DEGs) between WT and *Ifnlr1*<sup>-/-</sup> were selected by thresholding on fold change (+/-1.5) and *p* value (0.005). In heatmaps, DEGs were Z-scaled and clustered (Euclidean distance, Ward linkage). Pathway analysis was performed with the R package hypeR, using Gene Set Enrichment Analysis on genes ranked according to their  $\log_2(\text{Fold Change})$ .

### **Cell culture**

FLT3L-DCs were differentiated from bone marrow cells in Iscove's Modified Dulbecco's Media (IMDM; Thermo Fisher Scientific), supplemented with 30% B16-FLT3L derived supernatant and 10% fetal bovine serum (FBS) for 9 days.

Differentiated cells were stimulated with poly (I:C), R848, or 3p-hpRNA. Where indicated poly (I:C) and 3p-hpRNA were transfected with Lipofectamine 300 (Invitrogen #L3000015) according to manufacturer's instructions at the concentrations indicated in the figure legends. Where indicated poly (I:C) stimulated cells were pre-treated with 10 $\mu$ g/ml chloroquine for 5 minutes prior to stimulations.

### **qRT-PCR and ELISA**

RNA was isolated from cell cultures using a GeneJET RNA Purification Kit (Thermo Fisher Scientific #K0731) according to manufacturer's instructions. RNA was extracted from excised lungs by homogenizing them in 1ml of TRI Reagent. RNA was isolated from TRI Reagent samples using phenol-chloroform extraction or column-based extraction systems (Direct-zol RNA Microprep and Miniprep, Zymo Research #R2061 and #R2051) according to the manufacturer's protocol. RNA concentration and purity (260/280 and 260/230 ratios) were measured by NanoDrop (ThermoFisher Scientific).

Purified RNA was analyzed for gene expression on a CFX384 real-time cycler (Bio-Rad) using a TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific) or SYBR Green (Bio-Rad). Probes specific for *Ifnl2/3*, *Ifnb1*, *Il1b*, *Rsad2*, *Gapdh* were purchased from Thermo Fisher Scientific, and SYBR-Green primers for *Rsad2*, *Cxcl10*, *Gapdh* were purchased from Sigma. Cytokine analyses were carried out using homogenized lung supernatants, and cell supernatants from stimulated FLT3L-DCs. IFNA2/3 ELISA (R&D Systems DY1789B) and mouse IFN $\beta$ , IL1 $\beta$ , IL-6, TNF $\alpha$  ELISA (Invitrogen) were performed according to manufacturer's instructions.

### **Clinical samples**

Bronchoalveolar lavages (BAL) were obtained from five intensive care unit (ICU)-hospitalized SARS-CoV-2-positive patients. In parallel, five naso-oropharyngeal swabs were collected from both SARS-CoV-2-positive and -negative subjects. Among positive patients, two were hospitalized but without the need of ICU support, whereas three out of five did not require any hospitalization. The negative swabs were obtained from subjects undergoing screening for suspected social contacts with COVID-19 subjects. Swabs were performed by using FLOQSwabs® (COPAN) in UTM® Universal Transport Medium (COPAN). All samples were stored at -80°C until processing. The study involving human participants was reviewed and approved by San Raffaele Hospital IRB in the COVID-19 Biobanking project. The patients provided written informed consent.

### **RNA extraction protocol and Real-Time PCR of clinical samples**

RNA extraction was performed by using PureLink™ RNA Thermo Fisher Scientific according to manufacturers' instruction. In particular, 500  $\mu$ L for each BAL and swab analyzed sample were lysed and homogenized in the presence of RNase inhibitors. Then ethanol was added to homogenized samples which were further processed through a PureLink™ Micro Kit Column for RNA binding. After washing, purified total RNA was eluted in 28  $\mu$ L of RNase-Free Water.


Reverse transcription was then performed according to SuperScript™ III First-Strand Synthesis System (Invitrogen™) protocol by using 8 µL of RNA extracted from each BAL and swab sample. qRT-PCR analysis was then carried out for evaluating IL6, IL1B, IFNB1, IFNA2, IFNL1 and IFNL2 expression. All transcripts were tested in triplicate for each sample by using specific primers. GAPDH was also included. Real-time analysis was then performed according to manufacturer instructions by using TaqMan® Fast Advanced Master Mix (Applied Biosystems™ by Thermo Fisher Scientific). Real-Time PCR Analysis was performed on ABI 7900 by Applied Biosystems.

## Statistical Analyses

Statistical significance for experiments with more than two groups was tested with one-way ANOVA, and Dunnett's multiple-comparison tests were performed. Two-way ANOVA with Tukey's multiple-comparison test was used to analyze kinetic experiments. Two-way ANOVA with Sidak's multiple-comparison test was used to analyze experiments with 2 grouped variables (i.e. treatment, genotype). Statistical significance for survival curves were evaluated with the Log-rank (Mantel-Cox) test and corrected for multiple comparisons with Bonferroni's correction. To establish the appropriate test, normal distribution and variance similarity were assessed with the D'Agostino-Pearson omnibus normality test using Prism8 (Graphpad) software. When comparisons between only two groups were made, an unpaired two-tailed *t*-test was used to assess statistical significance. To determine the sample size, calculations were conducted in nQuery Advisor Version 7.0. Primary outcomes for each proposed experiment were selected for the sample size calculation and sample sizes adequate to detect differences with an 80% power were selected. For animal experiments, four to ten mice per group were used, as indicated in the figure legends.


## References.

69. G. Ortiz-Munoz, M. Looney, Non-invasive Intratracheal Instillation in Mice. *BIO-PROTOCOL.* **5** (2015), doi:10.21769/bioprotoc.1504.
70. F. Sun, G. Xiao, Z. Qu, Murine Bronchoalveolar Lavage. *BIO-PROTOCOL.* **7** (2017), doi:10.21769/bioprotoc.2287.
71. M. Gereke, A. Autengruber, L. Gröbe, A. Jeron, D. Bruder, S. Stegemann-Koniszewski, Flow Cytometric Isolation of Primary Murine Type II Alveolar Epithelial Cells for Functional and Molecular Studies. *J. Vis. Exp.*, e4322 (2012).




**Figure S1. Intratracheal poly (I:C) treatment induces morbidity and lung damage.**


(A) Weight change and (B) LDH released in BAL of WT mice treated daily with i.t. 0.5 mg/kg poly (I:C), 0.5 mg/kg R848 or saline for 6 days. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (A) Two-way ANOVA, (B) One-way ANOVA. (A) Mean and SEM of 5 mice per group is depicted. (B) Each mouse represents one point. Median and range are depicted.



**Figure S2. Intratracheal poly (I:C) treatment increases lung susceptibility to bacterial infection.** WT mice were treated daily with i.t. 0.5 mg/kg poly (I:C), 0.5 mg/kg R848 or saline for 6 days and infected i.t. with  $0.5 \times 10^8$  CFU of *S. aureus* at day 6. (A) Body temperature, (B) total protein in the BAL and *Ifnl2/3* (C), *Ifnb1* (D), *Il1b* (E) relative mRNA expression in total lung lysates were evaluated 12 hpi. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (One-way ANOVA). Each mouse represents one point. Median and range are depicted.




**Figure S3. IFN-λ protein levels correlate with susceptibility to bacterial infections.** (A-H) WT mice were treated daily for 1, 3, 5 or 6 days with i.t. 0.5 mg/kg poly (I:C) or 6 days of saline, and infected with i.t.  $0.5 \times 10^8$  CFU of *S. aureus* for 12h. Total lung homogenates were analyzed by qPCR for *ifnl2,3* (A), *ifnb1* (B), *Cxcl10* (F), *Rsad2* (G), *II1b* (H) relative mRNA expression. Protein levels of IFN-λ (C), IFN-β (D) and TNF-α (I) were evaluated by ELISA on lung homogenates. (E) Bacterial burden was evaluated in total lung homogenate. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (One-way ANOVA compared to Saline treatment). Each mouse represents one point. Median and range are depicted.




**Figure S4. IFN-λ signaling is necessary to confer poly (I:C)-induced morbidity and susceptibility to bacterial infections.** WT and *Ifnlr1*<sup>-/-</sup> mice were treated daily with i.t. 0.5 mg/kg poly (I:C) for 6 days and infected with i.t. 0.5 x 10<sup>8</sup> CFU of *S. aureus* for 12h. (A) Weight change, (B) total protein in the BAL, *Ifnl2,3* (C), *Ifnb1* (D), *Il1b* (E) relative mRNA expression, and IFN-λ (F), IFN-β (G) and TNF (H) production in total lung homogenate were evaluated.

Statistics: ns, not significant (P > 0.05); \*P < 0.05, \*\*P < 0.01 and \*\*\*P < 0.001 (Two-way ANOVA).


Each mouse represents one point. Median and range are depicted.




**Figure S5. IFN-λ acts on epithelial cell to induce lung damage.** Barrier function of chimeric mice *Ifnlr1<sup>-/-</sup>→Ifnlr1<sup>-/-</sup>*, *WT→Ifnlr1<sup>-/-</sup>*, *Ifnlr1<sup>-/-</sup>→WT*, and *WT→WT* were measured as RFU of FITC-dextran in the plasma of mice that were treated daily with i.t. 0.5 mg/kg poly (I:C) for 6 days and infected with i.t.  $0.5 \times 10^8$  CFU of *S. aureus* for 12h. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (One-way ANOVA). Each mouse represents one point. Median and range are depicted.



**Figure S6. IFN-λ dependent loss of tolerance against bacterial infections is independent of neutrophil function or alteration in immune cell recruitment.** Total number of (A) neutrophils (PMN), (B) Monocyte and monocyte derived cells (Mo), (C) alveolar macrophages (aMac) and (D) resident DC (resDCs) in lungs of WT and *Ifnrl1*<sup>-/-</sup> mice treated daily with i.t. 0.5 mg/kg poly (I:C) or saline for 6 days and infected with *S. aureus* as in Fig. 1K. (E) Wild-type mice were treated with either isotype or anti-Ly6G antibody to deplete Ly6G<sup>+</sup> neutrophils *in vivo*. Mice were treated with poly (I:C) or saline for 6 days and infected with i.t.  $0.5 \times 10^8$  CFU of *S. aureus* for 12h. Bacterial loads in the lungs were calculated as CFU per gram of lung weights. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (Two-way ANOVA). Each mouse represents one point. Median and range are depicted. Logarithmic data are fitted when depicting Bacterial load (E)




**Figure S7. Differentially expressed genes in WT versus *Ifnlr1*<sup>-/-</sup> lung epithelial cells from poly (I:C)-treated mice.** Heatmap of genes with a p-value < 0.005 and a Fold Change greater than 1.75 (or lower than -1.75) between *Ifnlr1*<sup>-/-</sup> and WT lung epithelial cells.




**Figure S8. Lung resident DCs are the primary producers of IFN- $\beta$  upon poly (I:C) treatment.**


Lungs of mice treated daily with i.t. 0.5 mg/kg poly (I:C) or saline for 6 days were sorted for epithelial cells (EC), resident DC (resDC), monocyte-derived DC (moDC), and alveolar macrophages (aMac) and assessed for (A) *Il1b* and (B) *Ifnb1* relative mRNA expressions. CD11c-DTR mice depleted for CD11c<sup>+</sup> cells *in vivo* by DTx injections were treated daily with i.t. 0.5 mg/kg poly (I:C) or saline for 6 days. Total lung lysates of the treated mice were analyzed for (C) *Ifnb1* relative mRNA expression, and (D) IFN- $\beta$  protein expression by ELISA. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (Two-way ANOVA). Mean and SEM of 5 mice per group are depicted.




**Figure S9. FLT3L-DCs responses to TLR3, RIG-I or TLR7 ligands.** FLT3L-DCs from WT, *Ticam1*<sup>-/-</sup> or *Mavs*<sup>-/-</sup> mice were treated with 50 $\mu$ g/ml poly (I:C), 1 $\mu$ g/ml transfected poly (I:C) or 50 $\mu$ g/ml R848 for 3h. *Ifnb1* (A), and *I1b* (B) relative mRNA expressions were evaluated by qPCR. Statistics: ns, not significant ( $P > 0.05$ ); \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (Two-way ANOVA). Mean and SEM of 3 independent experiments is depicted.



**Figure S10. FLT3L-DCs upregulate IFN-λ uniquely upon activation of TLR3 signaling and not in response to the RIG-I specific ligand 3p-hpRNA.** FLT3L-DCs from WT, *Ticam1*<sup>-/-</sup> or *Mavs*<sup>-/-</sup> mice were treated with 50μg/ml poly (I:C), or 1μg/ml transfected 3p-hpRNA for 3h or 6h. *Ifnl2,3* (A), *Ifnb1* (B), and *Il1b* (C) relative mRNA expressions were evaluated by qPCR after 3h. IFN-λ (D), and IFN-β (E) levels in the supernatants were evaluated by ELISA after 6h.



**Figure S11. The endosomal TLR inhibitor Chloroquine inhibits poly (I:C) dependent IFN- $\lambda$  expression in FLT3L-DCs.** FLT3L-DCs from WT mice were treated with 50 $\mu$ g/ml poly (I:C), or 1 $\mu$ g/ml transfected poly (I:C) for 3h in the presence or absence of 10 $\mu$ g/ml Chloroquine. *Ifn2*,3 (A), and *Ifnb1* (B) relative mRNA expressions were evaluated by qPCR.



**Figure S12. Sorting and cytofluorimetry strategy.** Depiction of gating strategy for cell sorting.

Cells were gated on FSC and SSC to eliminate debris, on FSC-A -FSC-H to select single cells and cells negative for live/dead dye and Lineage markers (CD3, CD19, Ter119). Epithelial cells were gated as  $CD45^- EpCAM^+ CD31^-$ . The  $EpCAM^-$  cells were sorted for immune cells as follows: aMac were gated as  $CD45^+ Ly6g^- CD11c^{hi} Siglec-F^+$ , monocytes and monocyte-derived cells (Mo) were gated as  $CD45^+ Ly6g^- Siglec-F^- Ly6C^+$ , cDCs were gated as  $CD45^+ Ly6g^- Siglec-F^- Ly6C^- CD11c^+ MHC-II^{hi}$ .